Research programme: uridine therapeutics - Repligen
Alternative Names: Anxiety disorder therapeutics - Repligen; Uridine analogues - Repligen; Uridine therapeutics - RepligenLatest Information Update: 11 Oct 2007
At a glance
- Originator Repligen
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Bipolar disorders
Most Recent Events
- 28 Oct 2004 Preclinical trials in Anxiety disorders in USA (unspecified route)